Global Biotechnology Contract Manufacturing Market Overview
The Biotechnology Contract Manufacturing Market size was valued at USD 16.3 Billion in 2022. The biotechnology contract manufacturing industry is projected to grow from USD 17.7 Billion in 2023 to USD 34.8 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.80% during the forecast period (2024 - 2032). Growing demand for biopharmaceuticals, increasing outsourcing of manufacturing activities, and globalization of the biopharmaceutical industry are the key market drivers that are enhancing market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Biotechnology Contract Manufacturing Market Trends
- Rising adoption of technologies in biotechnology contract manufacturing is driving the market growth
The rising adoption of technologies in biotechnology contract manufacturing is driving the market CAGR for this sector. Firstly, technological advancements have led to increased efficiency and scalability in biopharmaceutical manufacturing processes, allowing for cost-effective production and faster time-to-market for products. Additionally, advancements such as single-use technologies and continuous manufacturing systems offer flexibility and reduced capital investment. Moreover, the growing demand for personalized medicine and biologics further drives the need for innovative manufacturing solutions, stimulating the uptake of cutting-edge technologies in the biotechnology contract manufacturing sector.
For instance, In March 2023, Bristol Myers Squibb sent a selection of its protein-based medicines to the International Space Station with the aim to refine their production processes and improve the biomanufacturing of potent medicines, thus driving the Biotechnology contract manufacturing market revenue.
Additionally, pharmaceutical companies expand their operations internationally to access emerging markets and reduce production costs; they increasingly rely on contract manufacturing organizations (CMOs) to meet their manufacturing needs. This globalization trend fuels the demand for biotechnology contract manufacturing services. CMOs offer expertise, flexibility, and cost-effectiveness in producing biopharmaceuticals to meet diverse regulatory requirements across different regions, driving market expansion.
Biotechnology Contract Manufacturing Market Segment Insights
Biotechnology Contract Manufacturing Service Insights
The Biotechnology Contract Manufacturing Market segmentation, based on service, includes manufacturing, formulation & fill-finish, packaging & labeling, and other services. In 2023, the manufacturing segment dominated the market. It involves the outsourced production of biotechnological products, encompassing various stages from early development to commercialization. Biotechnology contract manufacturing facilitates cost-effective and scalable production solutions for pharmaceuticals, biologics, and other bio-based products, driving innovation and market expansion.
Biotechnology Contract Manufacturing Type Insights
The Biotechnology Contract Manufacturing Market segmentation, based on type, includes biologic drug substance manufacturing and biologic drug product manufacturing. In 2023, the biological drug substance manufacturing category generated the most income. Pharmaceutical and biotechnology companies seek biologic drug substance manufacturing services to leverage the specialized expertise, capacity, and resources offered by contract manufacturing organizations (CMOs) for efficient production processes.
Biotechnology Contract Manufacturing Scale of Operation Insights.
The Biotechnology Contract Manufacturing Market segmentation, based on the scale of operation, includes commercial operations and clinical operations. In 2023, the commercial operations category generated the most income. It pertains to companies engaged in large-scale production activities, often involving significant volumes of biopharmaceuticals or biotechnological products. These entities typically operate on a commercial scale, serving broad markets and often utilizing extensive manufacturing infrastructure to meet demand efficiently.
Figure 1: Biotechnology Contract Manufacturing Market, by Scale of Operation, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Biotechnology Contract Manufacturing Source Insights
The Biotechnology Contract Manufacturing Market segmentation, based on source, includes mammalian expression systems and non-mammalian expression systems. In 2023, the mammalian expression systems category generated the most income. Mammalian expression systems offer advantages such as proper protein folding and post-translational modifications, which are crucial for the production of complex biologics. As a result, they remain a preferred choice for manufacturing a wide range of biopharmaceutical products.
Biotechnology Contract Manufacturing Molecule Insights
The Biotechnology Contract Manufacturing Market segmentation, based on the molecule, includes monoclonal antibodies, cell therapy & gene therapy, antibody-drug conjugates (ADCs), vaccines, therapeutic peptides & proteins, and other molecule types. In 2023, the monoclonal antibodies category generated the most income. They represent a significant portion of this market, owing to their widespread applications in treating various diseases such as cancer, autoimmune disorders, and infectious diseases. Advancements in biotechnology and the expanding pipeline of monoclonal antibody-based therapeutics fuel this segment's growth.
Biotechnology Contract Manufacturing Therapeutic Area Insights.
The Biotechnology Contract Manufacturing Market segmentation, based on therapeutic areas, includes oncology, autoimmune diseases, cardiovascular diseases, metabolic diseases, infectious diseases, neurology, and other therapeutic areas. In 2023, the oncology category generated the most income. With increasing demand for advanced therapies and personalized medicine in cancer treatment, contract manufacturing services in oncology are witnessing significant growth. This segment emphasizes the importance of biotechnology contract manufacturing in delivering innovative solutions for combating cancer.
Biotechnology Contract Manufacturing Regional Insights.
By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American biotechnology contract manufacturing market area will dominate this market, owing to advanced infrastructure, technological innovation, and favorable regulatory frameworks. The region's established pharmaceutical and biotechnology industry, coupled with increasing outsourcing trends, propels market expansion. Further, the US biotechnology contract manufacturing market held the largest market share, and the Canadian biotechnology contract manufacturing market was the fastest-growing market in the North American region.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, and South Korea.
Figure 2: Biotechnology Contract Manufacturing Market Share By Region 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe biotechnology contract manufacturing market accounts for the second-largest market share due to increased outsourcing by biotech firms to reduce costs and focus on core competencies. Further, the German biotechnology contract manufacturing market held the largest market share, and the UK biotechnology contract manufacturing market was the fastest-growing market in the European region.
The Asia-Pacific biotechnology contract manufacturing market is expected to grow at the fastest CAGR from 2024 to 2032. This is due to the increasing demand for biopharmaceuticals, growing investments in R&D, and advancements in biotechnology. Moreover, China’s biotechnology contract manufacturing market held the largest market share, and the Indian biotechnology contract manufacturing market was the fastest-growing market in the Asia-Pacific region.
Biotechnology Contract Manufacturing Key Market Players & Competitive Insights.
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the biotechnology contract manufacturing market grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the biotechnology contract manufacturing industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global biotechnology contract manufacturing industry to benefit clients and increase the market sector. In recent years, the biotechnology contract manufacturing industry has offered some of the most significant advantages to medicine. Major players in the biotechnology contract manufacturing market, including Lonza (Switzerland), Thermo Fisher Scientific, Inc. (US), Catalent, Inc. (US), Samsung Biologics (South Korea), WuXi Biologics (China), Boehringer Ingelheim International GmbH (Germany), FUJIFILM Holding Corporation (Japan), AbbVie, Inc. (US), Eurofins Scientific (Luxembourg), AGC, Inc. (Japan), Merck KgaA (Germany), are attempting to increase market demand by investing in research and development operations.
WuXi Biologics, founded in 2015 and located in Shanghai, China, is a contract research development and manufacturing organization that provides open access and integrated technology platforms for drug development. It is a pharmaceutical industry and biotechnology company that serves worldwide. In January 2023, WuXi Biologics entered into a licensing agreement with GSK plc to use WuXi Biologics' proprietary technology platforms. Under this, GSK was granted an exclusive global license for the research, development, manufacturing, and commercialization of bispecific antibodies in the WuXi Biologics plan.
Samsung Biologics, founded in 2011 and located in Songdo, Incheon, South Korea, is a biotechnology company that provides contract development and manufacturing services to the pharmaceutical industry. It has partnered with multiple pharmaceutical companies for packaging and labeling purposes. Samsung Biologics is a biotech division of Samsung Group. In October 2022, Samsung Biologics partnered with GSK plc to manufacture GSK's monoclonal antibody and products, including lupus treatments like Benlysta.
Key Companies in the Biotechnology contract manufacturing market include
- Lonza (Switzerland)
- Thermo Fisher Scientific, Inc. (US)
- Catalent, Inc. (US)
- Samsung Biologics (South Korea)
- WuXi Biologics (China)
- Boehringer Ingelheim International GmbH (Germany)
- FUJIFILM Holding Corporation (Japan)
- AbbVie, Inc. (US)
- Eurofins Scientific (Luxembourg)
- AGC, Inc. (Japan)
- Merck KgaA (Germany)
Biotechnology contract manufacturing Industry Developments
In 2020: AstraZeneca and Oxford Biomedica signed a one-year clinical and commercial supply agreement for the manufacturing of AstraZeneca's COVID-19 vaccine candidate, AZD1222.
Biotechnology Contract Manufacturing Market Segmentation
Biotechnology Contract Manufacturing Service Outlook
- Manufacturing
- Formulation and Fill-Finish
- Packaging and Labeling
- Other services
Biotechnology Contract Manufacturing Type Outlook
- Biologic Drug Substance Manufacturing
- Biologic Drug Product Manufacturing
Biotechnology Contract Manufacturing Scale of Operation Outlook
- Commercial Operations
- Clinical Operations
Biotechnology Contract Manufacturing Source Outlook
- Mammalian Expression Systems
- Non-Mammalian Expression Systems
Biotechnology Contract Manufacturing Molecule Outlook
- Monoclonal Antibodies
- Cell Therapy & Gene Therapy
- Antibody-Drug Conjugates (ADCs)
- Vaccines
- Therapeutic Peptides & Proteins
- Other Molecule Types
Biotechnology Contract Manufacturing Therapeutic Area Outlook
- Oncology
- Autoimmune Diseases
- Cardiovascular Diseases
- Metabolic Diseases
- Infectious Diseases
- Neurology
- Other Therapeutic Areas
Biotechnology Contract Manufacturing Regional Outlook
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- Rest of the World
- Middle East
- Africa
- Latin America
| Report Attribute/Metric |
Details |
| Market Size 2022 |
USD 16.3 Billion |
| Market Size 2023 |
USD 17.7 Billion |
| Market Size 2032 |
USD 34.8 Billion |
| Compound Annual Growth Rate (CAGR) |
8.80% (2024-2032) |
| Base Year |
2023 |
| Market Forecast Period |
2024-2032 |
| Historical Data |
2019- 2022 |
| Market Forecast Units |
Value (USD Billion) |
| Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
Service, Type, Scale of operation, Source, Molecule, Therapeutic area and Region |
| Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered |
The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea |
| Key Companies Profiled |
Lonza (Switzerland), Thermo Fisher Scientific, Inc. (US), Catalent, Inc. (US), Samsung Biologics (South Korea), WuXi Biologics (China), Boehringer Ingelheim International GmbH (Germany), FUJIFILM Holding Corporation (Japan), AbbVie, Inc. (US), Eurofins Scientific (Luxembourg), AGC, Inc. (Japan), Merck KgaA (Germany) |
| Key Market Opportunities |
·        Rising emergence of personalized medicine and advanced therapies |
| Key Market Dynamics |
·        Formation of strategic partnerships and collaborations with biopharmaceutical companies |
Frequently Asked Questions (FAQ) :
The global market size was valued at USD 17.7 Billion in 2023.
The global market is projected to grow at a CAGR of 8.80% during the forecast period 2024-2032.
North America had the largest share of the global market.
The key players in the market are Lonza (Switzerland), Thermo Fisher Scientific, Inc. (US), Catalent, Inc. (US), Samsung Biologics (South Korea), WuXi Biologics (China), Boehringer Ingelheim International GmbH (Germany), FUJIFILM Holding Corporation (Japan), AbbVie, Inc. (US), Eurofins Scientific (Luxembourg), AGC, Inc. (Japan), Merck KgaA (Germany), and others.
The manufacturing category dominated the market in 2023.
Biologic drug substance manufacturing had the largest share of the global market.
The commercial operations category dominated the market in 2023.
The mammalian expression systems had the largest share in the global market.
The monoclonal antibodies had the largest share of the global market.
Oncology had the largest share of the global market.
